All News
Interesting study on Pioglitazone significantly improving vascular stiffness and cardiometabolic parameters vs. PBO in #lupus by @sarfarazhasni et al.
Pioglitazone: potential tx option to reduce CV risk in SLE?🧐
@RheumNow #ACR21 abs1748 https://t.co/ow3zA2hhnx
sheila RHEUMarampa ( View Tweet)
ePROs for SpA patients showed a trend in reduction of disease activity, improved clinic workload, individualized treatment with good patient/physician user satisfaction
Abs#1788
#ACR21 @RheumNow
https://t.co/04kUikdIZu https://t.co/uO9junUqKi
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Sleep disturbance common and associated with disease activity (both PRO and physician-assessed) in RA. Need further studies to evaluate causal directions, but may well be bidirectional? Abstr#1666 #ACR21 @RheumNow https://t.co/eK65I92wPg
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Ab#1683: ABA for RA-ILD
⭐️Stabilization of DLCO, FVC, HRCT in UIP and NSIP in 106 UIP, 84 NSIP patients
⭐️Stabilization or improvement of dyspnea in 91% UIP, 95% NSIP pts
@Rheumnow https://t.co/qfgDmooGOj https://t.co/gz6Jk15nUs
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Ab#1699: ITIS diet:
⭐️Fatigue ⬇️ in 20 pts on ITIS trial, didn't correlate with final DAS28CRP
⭐️Fatigue responders (50% improvement) had different fecal microbiome changes & anti-inflamm compounds, than non-responders
@Rheumnow https://t.co/UvE2ZpxCDU
Links:
Eric Dein ericdeinmd ( View Tweet)
For patients with inflammatory irAEs, what's your preference of bDMARD/tsDMARD?
(keeping in mind both irAE response and tumor response)
#ACR21 irAE Study Group run by @CCalabreseDO @NAbdelwahabMD @ReidMDMPH
@RheumNow
David Liew drdavidliew ( View Tweet)
☄️Late breakingTRAIL1 RCT Pirfenidone on RA-ILD.
✨Primary outcome on incidence of decline of >10% FVC or death not met 11% PIR vs. 15% PBO OR=0.67 p=0.48
BUT
✨underpowered
✨reduces decline in FVC(ml) over 52wk (-66 vs. -146, p=0.0082)
✨safety ok
#ACR21 #AbstL10
@RheumNow https://t.co/IxYDE3lN1s
Aurelie Najm AurelieRheumo ( View Tweet)
Safety update for #filgotinib in #RA over ~2.2yrs treatment
👉🏼Well-tolerated with no ne safety concerns since 2020
👉🏼AE incidence rates decreased or remained stable
👉🏼Slight incr rates of NMSC & non-NMSC malignancies
Abs#1698 #ACR21 @RheumNow
https://t.co/0jbZFVgiyN https://t.co/yOlntLwQlU
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#1655. Respiratory Ifn in RA on bDMARD
▶️1 group was initiated into vaccination program vs usual care
⭐️Vaccinated group had ⬇️ admissions from respiratory ifns. 44% ⬇️ severe resp ifn
💉programs work!
@Rheumnow https://t.co/pljR6DbAtU https://t.co/goSHGID8qG
Links:
Eric Dein ericdeinmd ( View Tweet)
Isolated axial involvement exists in 2-5% of PsA patients. In 576 patients 495 (31.4%) had axial disease, of which 32 (2.0%) had isolated axial disease. HLA-B*27+ and lower HAQ scores were associated with isolated axial disease @RheumNow #ACR21 Abst#1775 https://t.co/Y1EAJlA0mT https://t.co/8oZhN3mT30
Dr. Antoni Chan synovialjoints ( View Tweet)
In this study:
💊No correlation bet QTc interval & whole blood HCQ level regardless of dose, CKD or abnormal TTEs in #lupus pts
💊+correlation bet QTci & HCQ levels in pts w/ QTc prolonging drugs but not >456ms
Reassuring, dispels concern on HCQ use
@RheumNow #ACR21 abs1743 https://t.co/kpASRAXJB1
sheila RHEUMarampa ( View Tweet)
#Multimorbidity in women with #rheumatoidarthritis is increased compared to men with RA. However, women and men without RA have similar levels of multimorbidity.
Abs#1656 #ACR21 @RheumNow
https://t.co/iXhXOldTy0 https://t.co/CsOM7odE69
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#1658 - Autoimmune Risks in Relatives of RA pts. 1st degree relatives have risk of:
▶️ AI thyroid (OR 1.3)
▶️ Celiac (1.5)
▶️ SLE (1.3)
▶️ IBD - no ⬆️ risk
⭐️1st, 2nd, 3rd degree relativ: ⬆️ risk of RA
⭐️2nd degree: ⬆️ risk SLE
https://t.co/ATHdemoF45 @Rheumnow #ACRbest https://t.co/JcuZmg9L8E
Links:
Eric Dein ericdeinmd ( View Tweet)
GLORIA RCT: 400+ pts. Low dose Pred in RA >65yo on top of other treatments 2yrs.
Authors conclude benefit/risk balance in favour of GCs 🧐
2 thoughts:
1️⃣ CV risk linked to GCs ⬆️ over time and cumulative dose: Follow up= short!
2️⃣ Small # for CV events
#ACR21 #Abst 1678 @RheumNow https://t.co/QECJR68ZJu
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Deike on prevalence and incidence of PsA in Germany. Prevalence 5-6/1000. Incidence 30-40/100000. Marked age variations that don't really make sense for prevalence. Abstr#1785 #ACR21 @RheumNow https://t.co/uW0ruW2Jda
Richard Conway RichardPAConway ( View Tweet)
What is the likelihood of developing an #autoimmunedisease in first-degree relatives of pts with #RA?
Genealogical & phenotypic data suggests lower threshold for screening for autoimmune thyroiditis, #coeliac & #SLE in FDRs.
Abs#1658 #ACR21 @RheumNow
https://t.co/PdSZ05elsf https://t.co/AkIXDkWCM8
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts:
❌No ⬆️ in disease activity scores post-vaccination
❌No serious adverse event
▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls
⭐️RTX and MMF ⬇️ responses
@Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW
Links:
Eric Dein ericdeinmd ( View Tweet)
Dr Hebing on s/c vs oral methotrexate. erythrocyte methotrexate polyglutamates significantly higher with s/c administration. s/c consistently seems to be the better option, better efficacy, less side effects. Abstr#1695 #ACR21 @RheumNow https://t.co/kLGr6pVnxQ
Richard Conway RichardPAConway ( View Tweet)
Can we predict which PsO pts will develop PsA?
Machine learning and phenotyping of blood immune cell subsets identified an immune profile to discriminate PsO from PsA.
Abs#1774
#ACR21
@RheumNow
https://t.co/PERx86jjkJ https://t.co/oEpbMZ0nnK
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Congrats to Dr. Debaditya Roy, Dr. Chinenye Osuorji and Dr. Vaneet Sandhu on the leaderboard for engaged learning during #ACR21 @rheumnow
My points are pathetic compared to theirs and the top 10 https://t.co/yYppc029DM
TheDaoIndex KDAO2011 ( View Tweet)